Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, positive drug parallel-group controlled
clinical study in China to evaluate efficacy, safety, tolerability and immunogenicity of
HLX03 and adalimumab (Humira) in subjects with moderate to severe plaque psoriasis. This
study will recruit 216 subjects (18-75 years old, male and female) with moderate to severe
plaque psoriasis. The 216 subjects will be randomly assigned per 1:1 ratio into the following
two treatment groups (HLX03 OR Adalimumab). The study will be conducted in three periods,
including the screening period, treatment period and follow-up period. For each participating
subjects, the maximal length of the study will be 56 weeks (including up to four weeks of
screening time).